Among patients with baseline BMI of 35 or higher, discontinuation rates due to adverse events were 8.8% and 12.1% for the two doses compared to 4.8% with placebo
Rachot Vachathrone, MD , at Medallus Urgent Care offers transparent pricing for IV therapy, ensuring that patients are fully informed before receiving treatment
It only makes the work slightly easier, and once people see that, many stop seeing the point of paying for it at all
Tirzepatide does not directly worsen celiac disease, but its gastrointestinal side effects (nausea, diarrhea, abdominal discomfort) may overlap with celiac symptoms, particularly in patients with active disease or incomplete mucosal healing
Practical guidance for use of oral semaglutide in primary care: a narrative review